Benzinga
12 Dec 2025, 18:30 UTC · 46w ago
Impact · against what's priced in
RLAY is a strong positive catalyst as robust interim clinical data for zovegalisib and a significant analyst upgrade provide fundamental support for a higher valuation. RHHBY sees marginal positive sentiment from reports of a separate oral breast cancer drug's efficacy in reducing recurrence.
No priced-in read yet
What the story claims
4 claims · scored −1 bearish … +1 bullish
Wells Fargo upgraded Relay Therapeutics from Equal-Weight to Overweight and more than doubled its price target from $6 to $13.
More positive than 99% of claims this week
Interim clinical data for zovegalisib showed robust activity in PI3Kα-mutated breast cancer patients, including an ORR of 39% and median PFS of 10.3 months.
Continue reading
5 related stories
Interim data for zovegalisib shows a 39% ORR and 10.3 months median PFS in PI3Kα-mutated breast cancer, paired with a Wells Fargo upgrade to Overweight and a price target increase to $13.
Read from the article alone
No priced-in read yet
The company's oral breast cancer drug reportedly showed a 30% drop in recurrence for patients with early disease.
Read from the article alone
Scored by the NIS engine · methodology.
Search tags
More positive than 92% of claims this week
Zovegalisib has the potential to address a U.S. patient population of nearly 500,000 people if approved.
More positive than 76% of claims this week
Treatment-related adverse events for zovegalisib were primarily low-grade, manageable, and reversible.
More positive than 62% of claims this week
Which stocks this story touches
More positive than 95% of ticker scores this week
The company reported robust clinical data for its breast cancer drug and received a price target increase and upgrade from Wells Fargo.
More positive than 64% of ticker scores this week
Mentioned positively regarding an oral breast cancer drug that showed a 30% drop in recurrence.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Newsfile Corp
6h ago
+21.3%
Price agrees with the score
$60.66 vs $50.02 close before publication (Dec 11) · not market-adjusted
RHHBY chart →+123.7%
Price agrees with the score
$17.43 vs $7.79 close before publication (Dec 11) · not market-adjusted
RLAY chart →
